Ameriprise Financial Inc. lifted its stake in Quanterix Co. (NASDAQ:QTRX - Free Report) by 111.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,205,928 shares of the company's stock after purchasing an additional 1,688,680 shares during the period. Ameriprise Financial Inc. owned 8.32% of Quanterix worth $34,079,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also made changes to their positions in the company. JPMorgan Chase & Co. boosted its position in shares of Quanterix by 23.9% in the 4th quarter. JPMorgan Chase & Co. now owns 270,054 shares of the company's stock worth $2,871,000 after purchasing an additional 52,097 shares during the last quarter. Raymond James Financial Inc. bought a new position in Quanterix during the fourth quarter worth about $570,000. Barclays PLC lifted its holdings in Quanterix by 42.3% during the third quarter. Barclays PLC now owns 146,248 shares of the company's stock worth $1,896,000 after acquiring an additional 43,447 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in Quanterix by 219.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,702 shares of the company's stock worth $61,000 after acquiring an additional 3,915 shares in the last quarter. Finally, Envestnet Asset Management Inc. lifted its holdings in Quanterix by 22.5% during the fourth quarter. Envestnet Asset Management Inc. now owns 342,264 shares of the company's stock worth $3,638,000 after acquiring an additional 62,757 shares in the last quarter. 86.48% of the stock is currently owned by institutional investors.
Quanterix Trading Up 6.4%
Shares of Quanterix stock traded up $0.29 during trading on Friday, reaching $4.79. The stock had a trading volume of 734,544 shares, compared to its average volume of 566,619. The company has a market capitalization of $185.99 million, a price-to-earnings ratio of -4.52 and a beta of 1.12. The stock has a fifty day moving average price of $5.88 and a two-hundred day moving average price of $8.77. Quanterix Co. has a 52 week low of $4.05 and a 52 week high of $19.18.
Quanterix (NASDAQ:QTRX - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.53) EPS for the quarter, beating analysts' consensus estimates of ($0.69) by $0.16. The company had revenue of $30.33 million for the quarter, compared to analyst estimates of $28.27 million. Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. On average, equities analysts forecast that Quanterix Co. will post -0.98 EPS for the current fiscal year.
Analyst Ratings Changes
Several research analysts have weighed in on the company. Canaccord Genuity Group reduced their target price on Quanterix from $15.00 to $12.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. Leerink Partnrs lowered Quanterix from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 30th. Scotiabank reiterated an "outperform" rating on shares of Quanterix in a report on Tuesday, March 25th. Finally, Leerink Partners reiterated a "market perform" rating and set a $8.00 target price (down from $12.00) on shares of Quanterix in a report on Wednesday, April 30th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $15.60.
Read Our Latest Stock Report on QTRX
Quanterix Profile
(
Free Report)
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.
See Also
Before you consider Quanterix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quanterix wasn't on the list.
While Quanterix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
